BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

Executive Summary

• BioNxt Solutions Inc. announced a non‑binding LOI to acquire exclusive rights to a third‑party’s advanced drug chaperone technology for oral dissolvable applications.
• The acquisition is intended to enhance the company’s proprietary oral thin‑film (ODF) platform by improving drug stability, absorption efficiency, and formulation performance across multiple therapeutic areas.
• The LOI includes an exclusive right of first refusal for future non‑oral delivery formats and outlines BioNxt’s intent to fund development internally while pursuing licensing and co‑development opportunities.

Key Details

• Transaction Scope: Exclusive rights to variable‑affinity drug chaperone technology for oral dissolvable applications; optional right of first refusal for non‑oral formats.
• Strategic Rationale: Enhances ODF platform stability, absorption efficiency, and delivery consistency; expands lifecycle management opportunities; strengthens IP position, especially for neurological, autoimmune, infectious disease, and oncology indications.
• Therapeutic Targets Mentioned: Alzheimer’s, Parkinson’s, dementia, major depressive disorder, rheumatoid arthritis, lupus, diabetes, tuberculosis, solid tumors (breast, pancreatic, prostate), among others.
• Development Roadmap: Prototype development, future patent filings in Europe and the United States; internal funding of all activities.
• Status: Non‑binding LOI; definitive agreements yet to be negotiated and executed; no assurance that transaction will close on contemplated terms.
• CEO Quote: Hugh Rogers emphasized the strategic importance of securing chaperone technology to broaden reformulation capabilities and support a scalable, IP‑driven growth strategy.

Notable Quotes

“This initiative is strategically important for BioNxt. By securing rights to chaperone‑enabled delivery technology, we are strengthening our oral thin‑film platform and expanding the range of drug candidates that can be effectively reformulated into fast‑dissolving, swallow‑free formats…” – Hugh Rogers, CEO